No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Cognition Therapeutics, Inc. (CGTX) stock was $0.96 as of Oct 6, 2026, 10:04 AM EDT, up 2.31% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -39.3% · 3-year avg -10.8%/yr
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments.
Biotechnology · Purchase, NY
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.07
Revenue Est.
$5.30M
Last Quarter Results
EPS
$-0.04
vs Estimate
$-0.06
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CGTX | $85.90M | $0.96 | +2.31% | -39.33% | N/A | N/A | N/A |
| 2ACRV | $85.60M | $2.00 | +1.01% | +3.65% | N/A | N/A | vs CGTX |
| 3HUMA | $84.49M | $0.50 | +0.58% | -76.03% | -45.73% | N/A | vs CGTX |
| 4CRDF | $87.48M | $1.14 | -0.44% | -47.78% | -30.36% | -43.20% | vs CGTX |
| 5MNOV | $84.17M | $1.71 | -2.56% | +37.29% | -13.62% | -13.11% | vs CGTX |
| 6CCLD | $88.39M | $2.08 | +1.96% | -39.68% | -23.18% | +8.53% | vs CGTX |
forward FY estimate
N/A
$0.00
vs Estimate
$5.00M
Consensus Rating
Based on 3 analysts
Average Price Target
$3.33
+247.3% upside
Low
$3.00
Current
$0.96
High
$4.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.07 | $-0.07 | $-0.06 | 3 |
| Quarter ending Dec 2026 | $-0.25 | $-0.14 | $-0.05 | 3 |
| Quarter ending Mar 2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Quarter ending Jun 2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.42 | $-0.30 | $-0.20 | 3 |
| FY 2027 | $-0.25 | $-0.22 | $-0.19 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $5.30M | $5.30M | $5.30M | 1 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $18.30M | $18.30M | $18.30M | 2 |
| FY 2027 | $41.93M | $41.93M | $41.93M | 1 |
